From Burgwedel to Beni: The Global Battle Against Ebola

Share

The project will trace the line of the vaccination rVSV-ZEBOV from the first clinical trials to the patients in North Kivu, DRC. The journalists will describe the difficulties of fighting the virus and the advancements related.

  • €15,060 Budget in Euros
  • 2020 Final release date
  • 5 Round winner
  • 3 Locations
  • 2 Durations in months

The pharma company MSD plans to produce the entire dosage of the Ebola vaccination in Burgwedel. The project traces the line of the vaccination rVSV-EBOV from the production site to the patients and health workers in Democratic Republic of the Congo (DRC). At the same time, there is talk of a second vaccine being introduced. Within this dramaturgy, the project explains and highlights the work of the health professionals in DRC. The project accompanies some of MSF's doctors and nurses in DRC. It provides an explanation why some citizens are so weary of the vaccination and „la riposte“, the fight against Ebola itself. The citizens, according to MSF, have a multitude of problems – measles, for example. The project underlines how the nurses and doctors deal with the threat of Ebola, and how they manage to stay resilient and to fight a disease within an area of conflict.

Furthermore, the project accompanies David Gressly, the UN Ebola Emergency Response Coordinator to show why an area of conflict such as DRC needs other emergency responses than other places. Additionally, the project explains the sheer logistics of the vaccination: where it is stored, how it is transported to the citizens etc. (research still in progress). In addition, the project sheds light on the development of vaccination: how much work, research and time goes into the production of a vaccination?


Publications

Follow us and join the conversation